Copyright 2024
| PMID | Allele | Disease | Population | Drug Names | SNP | Class | Sentence |
|---|---|---|---|---|---|---|---|
| 25618241 | HLA-CLASS I (HLA-I) | prostate cancer | NA | NA | NA | negative | |
| tgf-b and egf induced hla-i downregulation is associated with epithelial-mesenchymal transition (emt) through upregulation of snail in prostate cancer cells. | |||||||
| 25618241 | HLA-CLASS I (HLA-I) | prostate cancer | NA | NA | NA | unclassified | |
| thus, we wondered whether tgf-b or egf was involved in the regulation of hla-i during the development of prostate cancer cells. | |||||||
| 25618241 | HLA-CLASS I (HLA-I) | prostate cancer | NA | NA | NA | negative | |
| in this study, we demonstrated that tgf-b and egf both downregulated the expression of hla-i, thereby attenuated the cytotoxic t cell mediated lysis of prostate cancer cells. | |||||||
| 25618241 | HLA-CLASS I (HLA-I) | prostate cancer | NA | NA | NA | negative | |
| taken together, this is the first evidence to reveal that both tgf-b and egf can induce hla-i downregulation which is then proven to be associated with emt in prostate cancer cells. | |||||||
| 25618241 | HLA-CLASS I (HLA-I) | prostate cancers | NA | NA | NA | negative | |
| downregulation of hla-i is observed in primary and metastatic prostate cancers, which facilitates them escape from immune surveillance, thereby promotes prostate cancer progression. | |||||||
| 25819666 | HLA-A*03 | prostate cancer | NA | NA | NA | unclassified | |
| new polycomb group protein enhancer of zeste homolog (ezh) 2-derived peptide with the potential to induce cancer-reactive cytotoxic t lymphocytes in prostate cancer patients with hla-a3 supertype alleles. | |||||||
| 25819666 | HLA-A*03 | prostate cancer | NA | NA | NA | unclassified | |
| in this study, we identified an enhancer of zeste homolog (ezh) 2-derived peptide applicable for anti-cancer vaccine for prostate cancer patients with hla-a3 supertype alleles. | |||||||
| 25819666 | HLA-A*33 | prostate cancer | NA | NA | NA | unclassified | |
| five ezh2-derived peptides that were prepared based on the binding motif to the hla-a3 supertype alleles (hla-a11, -a31, and -a33) were functionally screened for their potential to induce peptide-specific ctls from peripheral blood mononuclear cells (pbmcs) of hla-a3 supertype allele(+) prostate cancer patients. | |||||||
| 25819666 | HLA-A*11 | prostate cancer | NA | NA | NA | unclassified | |
| five ezh2-derived peptides that were prepared based on the binding motif to the hla-a3 supertype alleles (hla-a11, -a31, and -a33) were functionally screened for their potential to induce peptide-specific ctls from peripheral blood mononuclear cells (pbmcs) of hla-a3 supertype allele(+) prostate cancer patients. | |||||||
| 25819666 | HLA-A*31 | prostate cancer | NA | NA | NA | unclassified | |
| five ezh2-derived peptides that were prepared based on the binding motif to the hla-a3 supertype alleles (hla-a11, -a31, and -a33) were functionally screened for their potential to induce peptide-specific ctls from peripheral blood mononuclear cells (pbmcs) of hla-a3 supertype allele(+) prostate cancer patients. | |||||||
Copyright 2024